Global Markets Direct’s, 'Toxic Shock - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Toxic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Toxic Shock. Toxic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Toxic Shock. - A review of the Toxic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Toxic Shock pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Toxic Shock. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Toxic Shock pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Toxic Shock - Pipeline Review, H2 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Toxic Shock Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Toxic Shock 6 Toxic Shock Therapeutics under Development by Companies 8 Toxic Shock Therapeutics under Investigation by Universities/Institutes 9 Discovery and Pre-Clinical Stage Products 10 Comparative Analysis 10 Toxic Shock Therapeutics - Products under Development by Companies 11 Toxic Shock Therapeutics - Products under Investigation by Universities/Institutes 12 Companies Involved in Toxic Shock Therapeutics Development 13 Integrated BioTherapeutics, Inc. 13 Toxic Shock - Therapeutics Assessment 14 Assessment by Monotherapy Products 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Drug Profiles 19 TSS-HIG - Drug Profile 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 SEB-HuMab - Drug Profile 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 Monoclonal Antibody Against Staphylococcal Enterotoxin B - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Drug For Staphyloccal enterotoxin B And Toxic Shock Syndrome Toxin-1 - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 25 Disclaimer 25
List of Tables
Number of Products Under Development for Toxic Shock, H2 2013 6 Products under Development for Toxic Shock - Comparative Analysis, H2 2013 7 Number of Products under Development by Companies, H2 2013 8 Number of Products under Investigation by Universities/Institutes, H2 2013 9 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 10 Products under Development by Companies, H2 2013 11 Products under Investigation by Universities/Institutes, H2 2013 12 Integrated BioTherapeutics, Inc., H2 2013 13 Assessment by Monotherapy Products, H2 2013 14 Assessment by Stage and Route of Administration, H2 2013 16 Assessment by Stage and Molecule Type, H2 2013 18
List of Figures
Number of Products under Development for Toxic Shock, H2 2013 6 Products under Development for Toxic Shock - Comparative Analysis, H2 2013 7 Products under Development by Companies, H2 2013 8 Products under Investigation by Universities/Institutes, H2 2013 9 Discovery and Pre-Clinical Stage Products, H2 2013 10 Assessment by Monotherapy Products, H2 2013 14 Assessment by Route of Administration, H2 2013 15 Assessment by Stage and Route of Administration, H2 2013 16 Assessment by Molecule Type, H2 2013 17 Assessment by Stage and Molecule Type, H2 2013 18